Journal article · 2026 · Open access

Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor

Esther Chon, Mohamad Morsey, Terry Katz, Kazumi Yamada, Dennis Bailey, Philip J. Bergman, Holly Burr, Craig A. Clifford, Heather Heeb, Christina A. Manley, Brenda S. Phillips, Gerald S Post and 3 more

Journal of Veterinary Internal Medicine, 40(3) · Published 1 May 2026 · DOI 10.1093/jvimsj/aalag098

Open full textCite this paper

In brief

“Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor” is a 2026 journal article by Esther Chon and 14 co-authors, published in Journal of Veterinary Internal Medicine. OpenAlex counts 9 citations as of 17 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Veterinary Internal Medicine.

Citations
9
Most cited in
2026 (8)
Field-weighted impact
41.67
References
88
Authors
15

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed oncology in human medicine, providing clinical benefit in a broad spectrum of cancers. Widely available ICIs for dogs are lacking. HYPOTHESIS/OBJECTIVES: Evaluate efficacy and safety of gilvetmab, a caninized anti-PD-1 monoclonal antibody. ANIMALS: Fifty-one client-owned dogs were evaluated, 25 with stages II-III melanoma and 26 with stages I-III mast cell tumor (MCT). Fifteen dogs with stages III-V lymphoma were also evaluated. METHODS: Multi-institutional, open-label study. Enrolled dogs were treated with gilvetmab IV at 6 mg/kg q28d or 10 mg/kg q14d; 8 dogs receiving the lower dosage underwent dose escalation with their owners' consent. Safety was evaluated by physical examinations, laboratory testing, and clinical observations made by veterinarians or the dogs' owners. Efficacy was assessed by objective response rate (ORR) and time to progression (TTP) using cRECIST v1.0 and lymphoma response criteria. RESULTS: For melanoma, the ORR was 20% (95% confidence interval [CI], 7%-41%) and median TTP was 56 days. For MCT, the ORR was 46% (95% CI, 27%-67%) and median TTP was not reached. No objective responses were observed in dogs with lymphoma. Serious adverse events of anaphylaxis, hypotension, or tumor hemorrhage occurred in 3 dogs (3/51, 5.9%). Tumor enlargement before regression, consistent with possible pseudoprogression, was observed in 2 dogs with melanoma. CONCLUSIONS AND CLINICAL IMPORTANCE: Gilvetmab has a reasonable expectation of efficacy and an acceptable preliminary safety profile in dogs with MCT stages I-III and melanoma stages II and III.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chon, E., Morsey, M., Katz, T., Yamada, K., Bailey, D., Bergman, P. J., Burr, H., Clifford, C. A., Heeb, H., Manley, C. A., Phillips, B. S., Post, G. S., Vail, D. M., Rusk, A., & Stock, M. L. (2026). Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. Journal of Veterinary Internal Medicine, 40(3). https://doi.org/10.1093/jvimsj/aalag098

MLA 9

Chon, Esther, et al. “Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor.” Journal of Veterinary Internal Medicine, vol. 40, no. 3, 2026. https://doi.org/10.1093/jvimsj/aalag098.

Chicago

Chon, Esther, Mohamad Morsey, Terry Katz, Kazumi Yamada, Dennis Bailey, Philip J. Bergman, Holly Burr, et al. 2026. “Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor.” Journal of Veterinary Internal Medicine 40 (3). https://doi.org/10.1093/jvimsj/aalag098.

Harvard

Chon, E. et al. (2026) ‘Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor’, Journal of Veterinary Internal Medicine, 40(3). doi:10.1093/jvimsj/aalag098.

IEEE

E. Chon et al., “Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor,” Journal of Veterinary Internal Medicine, vol. 40, no. 3, 2026, doi: 10.1093/jvimsj/aalag098.

BibTeX

@article{chon2026efficacy,
  title     = {{Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor}},
  author    = {Chon, Esther and Morsey, Mohamad and Katz, Terry and Yamada, Kazumi and Bailey, Dennis and Bergman, Philip J. and Burr, Holly and Clifford, Craig A. and Heeb, Heather and Manley, Christina A. and Phillips, Brenda S. and Post, Gerald S and Vail, David M. and Rusk, Anthony and Stock, Matthew L.},
  journal   = {Journal of Veterinary Internal Medicine},
  year      = {2026},
  volume    = {40},
  number    = {3},
  doi       = {10.1093/jvimsj/aalag098},
  url       = {https://doi.org/10.1093/jvimsj/aalag098}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research

  • canine melanoma
  • canine mast cell tumors
  • immune checkpoint inhibitors
  • anti-PD-1 monoclonal antibody
  • dogs
  • lymphoma
  • objective response rate
  • time to progression

Work with this paper

Most-cited papers in Veterinary

All highly cited Veterinary papers

Questions about this paper

How do I cite this paper in APA style?

Chon, E., Morsey, M., Katz, T., Yamada, K., Bailey, D., Bergman, P. J., Burr, H., Clifford, C. A., Heeb, H., Manley, C. A., Phillips, B. S., Post, G. S., Vail, D. M., Rusk, A., & Stock, M. L. (2026). Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. Journal of Veterinary Internal Medicine, 40(3). https://doi.org/10.1093/jvimsj/aalag098

How many times has this paper been cited?

9 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Veterinary Internal Medicine: sign in and open the full text from this page.

Who wrote this paper?

Esther Chon, Mohamad Morsey, Terry Katz, Kazumi Yamada, Dennis Bailey, Philip J. Bergman, Holly Burr, Craig A. Clifford, Heather Heeb, Christina A. Manley, Brenda S. Phillips, Gerald S Post and 3 more.

What is the DOI of this paper?

10.1093/jvimsj/aalag098, permanently at https://doi.org/10.1093/jvimsj/aalag098. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.